Training Program in Pharmacology

药理学培训计划 摘要： 这个药理学博士前培训计划(TPPh)的首要目标是培养NEXT 药物发现和开发概念中的一代生物医学研究人员，包括 从临床角度来看。这种TPPh的四个重点领域是心血管、神经和免疫学 疾病和癌症。加州大学戴维斯分校是药物开发的世界领先者，拥有多名培训师带来药物 临床(最近是罗加夫斯基医生，一种新型的产后抗抑郁药Brexanolone)和生物制品 包括20项正在进行的临床试验的基因治疗载体(主任诺尔塔博士)。受训人员来自 药理学和毒理学、生理学、生物医学工程和神经科学在 不同的领域。领域包括经典药理学和使用尖端方法的药物靶标识别 生物化学、结构生物学、基因组学和蛋白质组学、分子和细胞生物学；结构建模和 合理药物设计；药物化学；高分辨率成像；电生理学；行为学 生理学；微流控设备和其他设备的工程；疾病的动物模型；新的活体整体 动物成像；临床试验中的转化疗法，包括干细胞和基因疗法。这个 TPPh将提供有重点的、为学生量身定做的药理学核心原则小组培训 面向非药理学实习生，并将这些学生与药理学专业的学生联系起来，进行跨学科学习 药物开发中的小组学习。一个相关的目标是使所有受训人员能够进行交流和协作 横跨他们所代表的大量研究学科。这一目标主要是在高度创新的情况下实现的 以学生为主导，以项目为导向的药理学课程问题解决，这使人焕发活力 每年都以学生的主动性和兴趣为基础。通过这种方式，我们的TPPh培养出了各种各样的专家 能够有效地与其他相关学科的专家进行交流和合作的背景 在日益复杂的药物开发领域。加州大学戴维斯分校授予更多学士和博士学位 生物科学学位比其他任何一所美国大学都要多。它收到了9.61亿美元的校外研究 在2020/21年度提供资金，这使它像前几年一样跻身十大公立大学之列。三十年的培训 教师来自6所学院的14个系，这些学院已经存在广泛的协作互动。 培训师提供深入的专业知识，范围从识别新的治疗分子靶点和 NIH资助的加州大学戴维斯分校临床药物和干细胞试验中治疗分子的发展 以及转化科学中心(CTSC)和NIH指定的癌症中心。强大而众多的国家- 最先进的核心设施和中心将为学员提供跨越以下领域的杰出研究机会 从化学对药物化学的重视到独特的动物模型(国际公认 老鼠生物中心、农业和兽医学校、灵长类中心)。

TRAINING PROGRAM IN PHARMACOLOGY ABSTRACT: The overarching goal of this predoctoral Training Program in Pharmacology (TPPh) is to educate next generation of biomedical researchers in the concepts of drug discovery and development, inclusive a clinical perspective. The four focus areas of this TPPh are cardiovascular, neurological, and immunological diseases and cancer. UC Davis is a world leader in drug development with multiple trainers bringing drugs to the clinic (most recently Dr. Rogawski the novel post-partum antidepressant Brexanolone) and biologics including gene therapy vectors with >20 ongoing clinical trials (Director Dr. Nolta). Trainees from Pharmacology & Toxicology, Physiology, Biomedical Engineering and Neuroscience develop expertise in diverse areas. Areas include classic pharmacology & drug target identification with cutting edge methods in biochemistry, structural biology, genomics & proteomics, molecular and cell biology; structural modeling and rational drug design; medicinal chemistry; high & superresolution imaging; electrophysiology; behavioral physiology; engineering of microfluidic and other devices; animal models of disease; novel in vivo whole animal imaging; and translational therapeutics in clinical trials including stem cell and genetic therapies. The TPPh will provide focused and student-tailored small group training in the core principles of pharmacology for non-pharmacology trainees, and enmesh these students with pharmacology students for interdisciplinary group learning in drug development. A related goal is to enable all trainees to communicate and collaborate across the large array of research disciplines they represent. This goal is mainly realized in a highly innovative student-driven, project-oriented course Problem Solving in Pharmacological Sciences, which rejuvenates itself every year based on student initiative and interest. In this way our TPPh produces experts with a variety of backgrounds that can effectively communicate and collaborate with experts from other related disciplines in the increasingly complex realm of drug development. UC Davis grants more bachelors and doctoral degrees in biological sciences than any other U.S. university. It received $961 million in extramural research funding in 2020/21, which places it, as in earlier years, among the top 10 public universities. The 30 training faculty are from 14 departments in 6 colleges, where extensive collaborative interactions already exist. Trainers provide in depth expertise that ranges from identifying novel therapeutic molecular targets and development of therapeutic molecules to clinical drug and stem cell trials at the NIH-funded UC Davis Clinical and Translational Science Center (CTSC) and NIH-designated Cancer Center. Powerful and numerous state- of-the-art core facilities and centers will provide trainees with outstanding research opportunities spanning from Chemistry’s emphasis on pharmaceutical chemistry to unique animal models (internationally recognized mouse biology center, Agricultural & Veterinary Schools, Primate Center).